FDA Grants Orphan Drug Designation to Natural Killer Cell Therapy for GI Cancers

The FDA granted orphan drug designation to CYNK-101, an investigational natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.